Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine for methamphetamine dependence
ACTRN12622000235707Phase 3Completed
- Sponsor
- University of New South Wales
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in methamphetamine use disorder (MUD) comparing Mirtazapine with Placebo (2 arms). Primary endpoint: Change in self-reported days of methamphetamine use in the past 28 days at Week 20. Started Nov 2022; status: completed.
02
Drugs
mirtazapine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on ACTRN12622000235707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000235707.